Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts By Watertime - March 12, 2026 2 Post Content RELATED ARTICLESMORE FROM AUTHOR After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions
